
Editorial: Chicago's Joffrey Ballet pirouettes to stability and growth
Consider. Like many ballet companies, the 70-year-old Joffrey makes its annual bones on 'The Nutcracker.' Last year, Christopher Wheeldon's adaptation, set during Chicago's 1893 World's Fair, brought in more than $7 million in ticket sales and played to more than 50,000 people. Since its debut in 2016, that annual production alone has grossed more than $30 million.
This spring, the exceptionally well-managed Joffrey risked more than $3 million on a new Wheeldon production of 'Alice's Adventures in Wonderland.' It paid off. It grossed $2.69 million in ticket sales just on this first go-around. 30,000 people bought tickets over the course of the 14-performance run. Most performances sold out; no mean feat for a venue with 3,520 seats.
All of that goes someway toward explaining why the Joffrey, which is run by artistic director Ashley Wheater and President and CEO Greg Cameron, has an annual operating budget of about $29 million and employs about 300 full- and part-time people in Chicago, does not carry a deficit, or struggle with debt.
Over the past 10 years, with the help of its board of directors, it has built up a total endowment of $32 million. Ten years ago it did not have any endowment at all.
There's another factor too: smart consolidation, a rarity in the arts.
On Wednesday, the ballet company told us it was extending its lease at the Lyric Opera House for seven more years through 2034, continuing an agreement that began in 2020 when Joffrey made the smart decision to move its main performance venue from the Auditorium Theatre.
This has been a win-win situation for both the Lyric and the Joffrey, creating a dynamic combination operating within a historic building that's a pivotal cultural anchor on the western edge of Chicago's Loop. Opera audiences are not as large as they once were, so runs are not as long and thus the Lyric had empty weeks, especially during the holiday period between the fall and spring opera seasons. Joffrey got the benefit of a massive stage, a grand auditorium with a huge capacity and an aesthetically pleasing environment.
The combination of ballet and opera in the same building is common in Europe (it occurs with the Royal Opera House and the Royal Ballet in London, among many others) but less so in the United States. Yet it makes perfect sense, not least because there is a big overlap between ballet and opera audiences. Not only can each company market to the other, they can share the heavy costs of live production, virtually year-round.
Tough as they have been for most peers, the last five years have been phenomenally successful for the Joffrey. This Chicago company is a balletic model for the nation.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Investors react to Trump's new reciprocal tariffs announcement
SINGAPORE (Reuters) -President Donald Trump signed an executive order on Thursday imposing reciprocal tariffs ranging from 10% to 41% on U.S. imports from dozens of countries and foreign locations. Rates were set at 25% for India's U.S.-bound exports, 20% for Taiwan's and 30% for South Africa's. Trump also signed an executive order on Thursday increasing tariffs on Canadian goods to 35% from 25%, the White House said. QUOTES: TONY SYCAMORE, MARKET ANALYST, IG, SYDNEY: "At this point, the reaction in markets has been modest, and I think part of the reason for that is the recent trade deals with the EU, Japan, and South Korea have certainly helped to cushion the impact, as has Mexico being granted a 90-day reprieve. And Trump said that trade talks with China are doing reasonably well there. "So on top of all of that, you have the TACO trade type situation whereby, after being obviously caught on the wrong foot in April, the market now, I think, has probably taken the view that these trade tariff levels can be renegotiated, can be walked lower over the course of time." BRIAN JACOBSEN, CHIEF ECONOMIST, ANNEX WEALTH MANAGEMENT, MENOMONEE FALLS, WISCONSIN (emailed comment): "Just because we now have clarity on the tariffs, that doesn't mean we have certainty about their effects. "There are those who think that tariff-induced consumer price inflation will slowly build as businesses work down inventories and test how strong their pricing power is. Others think the tariff-induced inflation will peak earlier, showing up mostly in crimped profit margins and resulting in slower growth. "However, what tariffs take with one hand, maybe tax incentives to invest and more open foreign markets can give with the other hand."
Yahoo
7 minutes ago
- Yahoo
Trump doubles down on Most Favored Nation plan to target drug prices
US President Donald Trump has called on pharmaceutical manufacturers to lower US drug prices in line with the Most Favored Nation (MFN) policy first proposed in an executive order in May. On 31 July, the White House said letters were sent to leading pharmaceutical manufacturers like AstraZeneca, AbbVie, Eli Lilly, Regeneron, Novartis, Pfizer, and more, calling on them to take steps to lower drug prices in the US such that they match the lowest prices in other developed countries within the next 60 days. President Trump also shared many of these letters on the social media platform Truth Social. While this is not the first time the administration has floated the MFN policy, this time, the language used to address pharma companies is more aggressive. If the companies do not comply, the order states, the federal government 'will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices.' In response to this statement, a spokesperson for the industry body BIO said, 'We share the Administration's goal of ending foreign freeloading on American innovation. But importing socialist price controls would lead only to fewer new medicines and the rationing of healthcare for Americans and would strengthen and embolden foreign adversaries whose goal is to dominate the world in biotechnology.' The BIO spokesperson said eliminating the middlemen, ending the abuse of drug reimbursement programs like 340B would be a way to simplify the system, protect patients and narrow the pricing gap between the US and other developed countries. 'Middlemen' or pharmacy benefit managers (PBMs) are often blamed by the pharmaceutical companies for high drug prices. PBMs on their part have said they negotiate with different stakeholders to drive down costs, and pass on savings obtained through rebates and discounts to health plans. The letter to the manufacturers implores them to provide drug at 'MFN rates' to all Medicaid patients, and commit to providing these prices for newly launched drugs to all major US buyers like Medicare and commercial plans. The latest announcement also calls on drug manufacturers to opt in for platforms where drugs can be sold directly to patients at prices that are comparable to those in developed nations, which are currently offered to third party payers. Among the letters posted on Truth Social, Trump directly called on several CEOs like Albert Bourla of Pfizer, and Leonard Schleifer of Regeneron, by using their first names instead of a formal address. Several countries use international reference pricing as a strategy in their health systems. However, chief among the criticism following the May executive order has been the lack of details. Industry experts have highlighted a lack of clarity on how any potential list price changes will affect the prices patients pay at the pharmacy counter given the complex dynamics and multiple stakeholders in the US healthcare system. There is also a concern that if the US implements reference pricing, it could influence when companies choose to launch drugs in certain ex-US markets to avoid those potentially lower prices from being used as references. Furthermore, pharma companies have chosen the litigation route to fight legislative changes targeting drug prices, like the Inflation Reduction Act, and the same could be seen with the MFN executive order, as per a Bank of America report. "Trump doubles down on Most Favored Nation plan to target drug prices" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. 登入存取你的投資組合
Yahoo
7 minutes ago
- Yahoo
South Korea July exports beat forecast on strong chip demand
SEOUL (Reuters) -South Korea's exports rose for the second straight month in July, beating market expectations on strong chip demand, trade data showed on Friday. Exports from Asia's fourth-largest economy, an early bellwether for global trade, rose 5.9% from the same month last year to $60.82 billion, stronger than the 4.3% increase in June and a 4.6% forecast for July in a Reuters poll of economists. In July, there were signs of front-loading ahead of an August 1 deadline for higher U.S. tariffs, economists said. President Donald Trump signed an executive order on Thursday imposing reciprocal tariffs ranging from 10% to 41% on U.S. imports from dozens of countries and foreign locations. With South Korea, Trump signed a trade deal on Wednesday lowering tariffs to 15% from a threatened 25%, which officials, companies and economists cheered for reducing uncertainty over the trade environment. Exports of semiconductors jumped 39.3% in July, the biggest annual increase since October 2024, while cars rose 8.8% on robust demand in non-U.S. markets. Ship exports surged 107.6%. By destination, shipments to the U.S. rose 1.4%, as growing technology demand offset the impact of Trump's tariffs on steel and auto parts. Exports to China fell 3.0%, while those to the European Union rose 8.7%. Imports rose 0.7% in July to $54.21 billion, compared with a gain of 4.3% in June and 2.0% expected by economists. The monthly trade balance stood at a surplus of $6.61 billion, narrower than the previous month's $9.08 billion, which was the biggest since September 2018. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data